Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies

Prostate Cancer

Volumn 2016, Issue , 2016, Pages

  Juloori, Aditya ^a   Shah, Chirag ^a   Stephans, Kevin ^a   Vassil, Andrew ^a   Tendulkar, Rahul ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CONSENSUS; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; LYMPH NODE IRRADIATION; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PELVIS LYMPH NODE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME;

EID: 85006226977     PISSN: 20903111     EISSN: 2090312X     Source Type: Journal    
DOI: 10.1155/2016/2420786     Document Type: Review

References (84)

1. American Cancer Society, Prostate Cancer, 2015, http://www. cancer. org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics.
2. J. L. Mohler, P. W. Kantoff, A. J. Armstrong et al., "Prostate cancer, version 2. 2014, " Journal of the National Comprehensive Cancer Network, vol. 12, no. 5, pp. 686-718, 2014.
3. M. J. Zelefsky, V. E. Reuter, Z. Fuks, P. Scardino, and A. Shippy, "Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer, " Journal of Urology, vol. 179, no. 4, pp. 1368-1373, 2008.
4. J. J. Coen, A. L. Zietman, H. Thakral, and W. U. Shipley, "Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases, " Journal of Clinical Oncology, vol. 20, no. 15, pp. 3199-3205, 2002.
5. A. Widmark, O. Klepp, A. Solberg et al., "Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial, " The Lancet, vol. 373, no. 9660, pp. 301-308, 2009.
6. P. Warde, M. Mason, K. Ding et al., "Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial, " The Lancet, vol. 378, no. 9809, pp. 2104-2111, 2011.
7. M. D. Mason, W. R. Parulekar, M. R. Sydes et al., "Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer, " Journal of Clinical Oncology, vol. 33, no. 19, pp. 2143-2150, 2015.
8. U. E. Studer, P. Whelan, W. Albrecht et al., "Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891, " Journal of Clinical Oncology, vol. 24, no. 12, pp. 1868-1876, 2006.
9. I. Thompson, J. B. Thrasher, G. Aus et al., "Guideline for the management of clinically localized prostate cancer: 2007 update, " Journal of Urology, vol. 177, no. 6, pp. 2106-2131, 2007.
10. M. D. Brundage, M. R. Sydes, W. R. Parulekar et al., "Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial, " Journal of Clinical Oncology, vol. 33, no. 19, pp. 2151-2157, 2015.
11. M. V. Pilepich, R. Caplan, R. W. Byhardt et al., "Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31, " Journal of Clinical Oncology, vol. 15, no. 3, pp. 1013-1021, 1997.
12. M. V. Pilepich, K. Winter, C. A. Lawton et al., "Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31, " International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1285-1290, 2005.
13. M. V. Pilepich, W. T. Sause, W. U. Shipley et al., "Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the radiation therapy oncology group, " Urology, vol. 45, no. 4, pp. 616-623, 1995.
14. M. V. Pilepich, K. Winter, M. J. John et al., "Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate, " International Journal of Radiation Oncology Biology Physics, vol. 50, no. 5, pp. 1243-1252, 2001.
15. M. Roach III, K. Bae, J. Speight et al., "Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-termresults of RTOG 8610, " Journal of Clinical Oncology, vol. 26, no. 4, pp. 585-591, 2008.
16. J. W. Denham, A. Steigler, D. S. Lamb et al., "Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96. 01 randomised controlled trial, " The Lancet Oncology, vol. 6, no. 11, pp. 841-850, 2005.
17. M. Bolla, D. Gonzalez, P. Warde et al., "Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin, " The New England Journal of Medicine, vol. 337, no. 5, pp. 295-300, 1997.
18. M. Bolla, G. Van Tienhoven, P. Warde et al., "External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, " The Lancet Oncology, vol. 11, no. 11, pp. 1066-1073, 2010.
19. M. Bolla, T. M. de Reijke, G. Van Tienhoven et al., "Duration of androgen suppression in the treatment of prostate cancer, " The NewEngland Journal ofMedicine, vol. 360, no. 24, pp. 2516-2527, 2009.
20. G. E. Hanks, T. F. Pajak, A. Porter et al., "Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02, " Journal of Clinical Oncology, vol. 21, no. 21, pp. 3972-3978, 2003.
21. E. M. Horwitz, K. Bae, G. E. Hanks et al., "Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer, " Journal of Clinical Oncology, vol. 26, no. 15, pp. 2497-2504, 2008.
22. A. Zapatero, A. Guerrero, X. Maldonado et al., "High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial, " The Lancet Oncology, vol. 16, no. 3, pp. 320-327, 2015.
23. A. Nabid, N. Carrier, A.-G. Martin et al., "Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial, " Journal of Clinical Oncology, vol. 31, supplement, abstract LBA4510, 2013.
24. D. A. Kuban, S. L. Tucker, L. Dong et al., "Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer, " International Journal of Radiation Oncology Biology Physics, vol. 70, no. 1, pp. 67-74, 2008.
25. A. Al-Mamgani, W. L. J. van Putten, W. D. Heemsbergen et al., "Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer, " International Journal of Radiation Oncology, Biology, Physics, vol. 72, no. 4, pp. 980-988, 2008.
26. S. T. H. Peeters, W. D. Heemsbergen, P. C. M. Koper et al., "Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapywith78Gy, " Journal of Clinical Oncology, vol. 24, no. 13, pp. 1990-1996, 2006.
27. D. P. Dearnaley, M. R. Sydes, J. D. Graham et al., "Escalateddose versus standard-dose conformal radiotherapy in prostate cancer: first results from theMRC RT01 randomised controlled trial, " The Lancet Oncology, vol. 8, no. 6, pp. 475-487, 2007.
28. D. P. Dearnaley, G. Jovic, I. Syndikus et al., "Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial, " The Lancet Oncology, vol. 15, no. 4, pp. 464-473, 2014.
29. M. Roach III, M. DeSilvio, C. Lawton et al., "Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation Therapy Oncology Group 9413, " Journal of Clinical Oncology, vol. 21, no. 10, pp. 1904-1911, 2003.
30. C. A. Lawton, M. DeSilvio, M. Roach III et al., "An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions, " International Journal of Radiation Oncology, Biology, Physics, vol. 69, no. 3, pp. 646-655, 2007.
31. M. Roach, D. Hunt, C. A. Lawton et al., "Radiation Therapy Oncology Group (RTOG) 9413: A randomized trial comparing Whole Pelvic Radiation Therapy (WPRT) to Prostate only (PORT) and Neoadjuvant Hormonal Therapy (NHT) to Adjuvant Hormonal Therapy (AHT), " International Journal of Radiation Oncology, Biology, Physics, vol. 87, no. 2, pp. S106-S107, 2013.
32. P. Pommier, S. Chabaud, J. L. Lagrange et al., "Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01, " Journal of Clinical Oncology, vol. 25, no. 34, pp. 5366-5373, 2007.
33. A. A. Aizer, J. B. Yu, A. M. McKeon, R. H. Decker, J. W. Colberg, and R. E. Peschel, "Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma, " International Journal of Radiation Oncology, Biology, Physics, vol. 75, no. 5, pp. 1344-1349, 2009.
34. M. Roach III, C. Marquez, H.-S. Yuo et al., "Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer, " International Journal of Radiation Oncology, Biology, Physics, vol. 28, no. 1, pp. 33-37, 1994.
35. J. W. Denham, A. Steigler, D. S. Lamb et al., "Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96. 01 randomised trial, " The Lancet Oncology, vol. 12, no. 5, pp. 451-459, 2011.
36. L. Souhami, K. Bae, M. Pilepich, and H. Sandler, "Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis ofRTOG85-31, " Journal ofClinicalOncology, vol. 27, no. 13, pp. 2137-2143, 2009.
37. A. Konski, D. Watkins-Bruner, H. Brereton, S. Feigenberg, and G. Hanks, "Long-term hormone therapy and radiation is costeffective for patients with locally advanced prostate carcinoma, " Cancer, vol. 106, no. 1, pp. 51-57, 2006.
38. NCCN Guidelines for Patients, Prostate Cancer. November 2015, http://www. nccn. org/patients/guidelines/prostate/index. html.
39. C. A. Lawton, K. Bae, M. Pilepich, G. Hanks, and W. Shipley, "Long-term treatment sequelae after external beam irradiation with or without hormonalmanipulation for adenocarcinoma of the prostate: Analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02, " International Journal of Radiation Oncology Biology Physics, vol. 70, no. 2, pp. 437-441, 2008.
40. A. V. D'Amico, J. W. Denham, J. Crook et al., "Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions, " Journal of Clinical Oncology, vol. 25, no. 17, pp. 2420-2425, 2007.
41. P. L. Nguyen, Y. Je, F. A. B. Schutz et al., "Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials, " The Journal of the AmericanMedical Association, vol. 306, no. 21, pp. 2359-2366, 2011.
42. G. N. Levine, A. V. D'Amico, P. Berger et al., "Androgendeprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American heart association, American cancer society, and American urological association: Endorsed by the American society for radiation oncology, " CA-A Cancer Journal for Clinicians, vol. 60, no. 3, pp. 194-201, 2010.
43. N. H. Lester-Coll, S. Z. Goldhaber, D. J. Sher, and A. V. D'Amico, "Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: A decision analysis, " Cancer, vol. 119, no. 10, pp. 1808-1815, 2013.
44. A. L. Zietman, K. Bae, J. D. Slater et al., "Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: longterm results from proton radiation oncology group/american college of radiology 95-09, " Journal of Clinical Oncology, vol. 28, no. 7, pp. 1106-1111, 2010.
45. J. M. Michalski, Y. Yan, D. Watkins-Bruner et al., "Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial, " International Journal of Radiation Oncology Biology Physics, vol. 87, no. 5, pp. 932-938, 2013.
46. M. C. Abramowitz, T. Li, M. K. Buyyounouski et al., "The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer, " Cancer, vol. 112, no. 1, pp. 55-60, 2008.
47. M. J. Zelefsky, Y. Yamada, Z. Fuks et al., "Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes, " International Journal of Radiation Oncology Biology Physics, vol. 71, no. 4, pp. 1028-1033, 2008.
48. A. Amini, B. L. Jones, N. Yeh, C. G. Rusthoven, H. Armstrong, and B. D. Kavanagh, "Survival outcomes of whole-pelvic versus prostate-only radiation therapy for high-risk prostate cancer patients with use of the national cancer data base, " International Journal of Radiation Oncology, Biology, Physics, vol. 93, no. 5, pp. 1052-1063, 2015.
49. G. K. Zagars, A. Pollack, and A. C. von Eschenbach, "Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer, " Urology, vol. 58, no. 2, pp. 233-239, 2001.
50. C. A. Lawton, K. Winter, D. Grignon, and M. V. Pilepich, "Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31, " Journal of Clinical Oncology, vol. 23, no. 4, pp. 800-807, 2005.
51. J. D. Tward, K. E. Kokeny, and D. C. Shrieve, "Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival, " Practical Radiation Oncology, vol. 3, no. 3, pp. 234-240, 2013.
52. C. G. Rusthoven, J. A. Carlson, T. V. Waxweiler et al., "The impact of definitive local therapy for lymph node-positive prostate cancer: A population-based study, " International Journal of Radiation Oncology, Biology, Physics, vol. 88, no. 5, pp. 1064-1073, 2014.
53. A. Briganti, R. J. Karnes, L. F. Da Pozzo et al., "Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis, " European Urology, vol. 59, no. 5, pp. 832-840, 2011.
54. F. Abdollah, R. J. Karnes, N. Suardi et al., "Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer, " Journal of Clinical Oncology, vol. 32, no. 35, pp. 3939-3947, 2014.
55. J. R. Kaplan, K. J. Kowalczyk, T. Borza et al., "Patternsof care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy, " BJU International, vol. 111, no. 8, pp. 1208-1214, 2013.
56. W. B. van den Hout, G. W. P. M. Kramer, E. M. Noordijk, and J.-W. H. Leer, "Cost-utility analysis of short-versus longcourse palliative radiotherapy in patients with non-small-cell lung cancer, " Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1786-1794, 2006.
57. T. B. Lanni, I. S. Grills, L. L. Kestin, and J. M. Robertson, "Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer, " American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 34, no. 5, pp. 494-498, 2011.
58. S. Aluwini, F. Pos, E. Schimmel et al., "Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial, " The Lancet Oncology, vol. 16, no. 3, pp. 274-283, 2015.
59. H. Lukka, C. Hayter, J. A. Julian et al., "Randomized trial comparing two fractionation schedules for patients with localized prostate cancer, " Journal of Clinical Oncology, vol. 23, no. 25, pp. 6132-6138, 2005.
60. E. E. Yeoh, R. J. Botten, J. Butters, A. C. DiMatteo, R. H. Holloway, and J. Fowler, "Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial, " International Journal of Radiation Oncology Biology Physics, vol. 81, no. 5, pp. 1271-1278, 2011.
61. K. E. Hoffman, K. R. Voong, T. J. Pugh et al., "Risk of Late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial, " International Journal of Radiation Oncology, Biology, Physics, vol. 88, no. 5, pp. 1074-1084, 2014.
62. A. Pollack, G. Walker, E. M. Horwitz et al., "Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer, " Journal of Clinical Oncology, vol. 31, no. 31, pp. 3860-3868, 2013.
63. S. Arcangeli, L. Strigari, S. Gomellini et al., "Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer, " International Journal of Radiation Oncology, Biology, Physics, vol. 84, no. 5, pp. 1172-1178, 2012.
64. G. Arcangeli, J. Fowler, S. Gomellini et al., "Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer, " International Journal of Radiation Oncology Biology Physics, vol. 79, no. 4, pp. 1013-1021, 2011.
65. L. Incrocci, R. C. Wortel, S. Aluwini et al., "Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five-year oncologic outcomes of the dutch randomized phase 3 HYPRO trial, " International Journal of Radiation Oncology, Biology, Physics, vol. 94, no. 1, pp. 1-2, 2016.
66. S. Aluwini, F. Pos, E. Schimmel et al., "Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial, " The Lancet Oncology, vol. 16, no. 3, pp. 274-283, 2016.
67. A. Bossi and P. Blanchard, "Hypofractionation for prostate cancer: A word of caution, " The Lancet Oncology, vol. 17, no. 4, pp. 406-407, 2016.
68. A. Wilkins, H. Mossop, I. Syndikus et al., "Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, noninferiority, phase 3 CHHiP trial, " The Lancet Oncology, vol. 16, no. 16, pp. 1605-1616, 2015.
69. D. Norkus, A. Karklelyte, B. Engels et al., "A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients, " Radiation Oncology, vol. 8, article 206, 2013.
70. A. Martinez, J. Gonzalez, W. Spencer et al., "Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors, " The Journal of Urology, vol. 169, no. 3, pp. 974-980, 2003.
71. D. J. Demanes, R. R. Rodriguez, L. Schour, D. Brandt, and G. Altieri, "High-dose-rate intensity-modulated brachytherapy with external beamradiotherapy for prostate cancer: California endocurietherapy's 10-year results, " International Journal of RadiationOncology, Biology, Physics, vol. 61, no. 5, pp. 1306-1316, 2005.
72. R. M. Galalae, G. Kovács, J. Schultze et al., "Long-termoutcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer, " International Journal of Radiation Oncology, Biology, Physics, vol. 52, no. 1, pp. 81-90, 2002.
73. R. Martínez-Monge, M. Moreno, R. Ciérvide et al., "Externalbeam radiation therapy and high-dose rate brachytherapy combined with long-termandrogen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome, " International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 3, pp. e469-e476, 2012.
74. W. J. Morris, S. Tyldesley, H. H. Pai et al., "ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer, " Journal of Clinical Oncology, vol. 33, supplement 7, abstract 3, 2015.
75. T. P. Boike, Y. Lotan, L. C. Cho et al., "Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer, " Journal of Clinical Oncology, vol. 29, no. 15, pp. 2020-2026, 2011.
76. C. R. King, D. Freeman, I. Kaplan et al., "Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials, " Radiotherapy and Oncology, vol. 109, no. 2, pp. 217-221, 2013.
77. C. R. King, S. Collins, D. Fuller et al., "Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results fromamulti-institutional consortiumof prospective trials, " International Journal of Radiation Oncology, Biology, Physics, vol. 87, no. 5, pp. 939-945, 2013.
78. G. Bauman, M. Ferguson, M. Lock et al., "A phase 1/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer, " International Journal of Radiation Oncology, Biology, Physics, vol. 92, no. 4, pp. 856-862, 2015.
79. R. Kotecha, T. Djemil, R. D. Tendulkar et al., "Dose-escalated stereotactic body radiation therapy for patients with intermediate and high-risk prostate cancer: initial dosimetry analysis and patient outcomes, " International Journal of Radiation Oncology, Biology, Physics, 2016.
80. V. Fonteyne, G. Villeirs, B. Speleers et al., "Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalationwith simultaneous integrated boost to intraprostatic lesion, " International Journal of Radiation Oncology, Biology, Physics, vol. 72, no. 3, pp. 799-807, 2008.
81. A. K. Singh, P. Guion, N. Sears-Crouse et al., "Simultaneous integrated boost of biopsy proven, MRI defined dominant intraprostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study, " Radiation Oncology, vol. 2, article 36, 2007.
82. A. Gomez-Iturriaga, F. Casquero, A. Urresola et al., "Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial, " Radiotherapy and Oncology, vol. 119, no. 1, pp. 91-96, 2016.
83. P. L. Nguyen, M.-H. Chen, Y. Zhang et al., "Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy, "TheJournal ofUrology, vol. 188, no. 4, pp. 1151-1156, 2012.
84. S. Aluwini, P. van Rooij, M. Hoogeman, W. Kirkels, I.-K. Kolkman-Deurloo, and C. Bangma, "Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low-and intermediate-risk prostate cancer: early results, " Radiation Oncology, vol. 8, article 84, 2013.